NCT01886859View on ClinicalTrials.gov

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 26, 2013

Primary Completion Date

November 15, 2020

Study Completion Date

September 21, 2022

Conditions

Recurrent B-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory B-Cell Prolymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

DRUG

Lenalidomide

Given PO

Trial Locations (3)

43210

Ohio State University Comprehensive Cancer Center, Columbus

80045

University of Colorado Hospital, Aurora

94304

Stanford Cancer Institute Palo Alto, Palo Alto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT01886859 - Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter